CTO
Medicilon
Lexington, Massachusetts
With over 27 years of experience in preclinical drug development, Dr. Xu is the CTO of Medicilon. She leads technological innovation and global expansion, strengthening its capabilities to deliver cutting-edge R&D solutions. Dr. Xu, who holds a Ph.D. in Biology from St Louis University, is a recognized expert in pharmacokinetics, toxicology, and drug metabolism. She has successfully led numerous global drug development programs from early discovery through clinical stages and held leadership roles at major pharmaceutical and biotech companies, including Pharmaron, Icagen, Purdue Pharma, Sanofi, and Amgen.
Disclosure information not submitted.
Integrated Preclinical CRO Strategies: From Target Engagement to IND
Monday, November 10, 2025
11:15 AM - 12:00 PM CT